Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 4:46 PM
Ignite Modification Date:
2025-12-25 @ 2:32 PM
NCT ID:
NCT01004250
Group ID:
EG002
Title:
Overall Study Treatment
Description:
Induction Therapy:
Bevacizumab: 7.5 mg/kg given intravenously on Day 1 for four cycles (cycle=21 days) of Induction Therapy.
Pemetrexed: 500 mg/m² given intravenously on Day 1 for four cycles of Induction Therapy.
Cisplatin: 75 mg/m² given intravenously on Day 1 for a maximum of 4 cycles.
Maintenance Therapy:
Bevacizumab: 7.5 mg/kg given intravenously on Day 1 of each cycle and continued until progression or unacceptable toxicity.
Pemetrexed: 500 mg/m² given intravenously on Day 1 of each cycle and continued until progression or unacceptable toxicity.
Deaths Number Affected:
None
Deaths Number At Risk:
None
Serious Number Affected:
39
Serious Number At Risk:
109
Other Number Affected:
106
Other Number At Risk:
109
Study:
NCT01004250
Results Section:
NCT01004250
Adverse Events Module:
NCT01004250